The impact of founder personalities on startup success.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 10 2023
Historique:
received: 15 02 2023
accepted: 04 09 2023
medline: 23 10 2023
pubmed: 18 10 2023
entrez: 17 10 2023
Statut: epublish

Résumé

Startup companies solve many of today's most challenging problems, such as the decarbonisation of the economy or the development of novel life-saving vaccines. Startups are a vital source of innovation, yet the most innovative are also the least likely to survive. The probability of success of startups has been shown to relate to several firm-level factors such as industry, location and the economy of the day. Still, attention has increasingly considered internal factors relating to the firm's founding team, including their previous experiences and failures, their centrality in a global network of other founders and investors, as well as the team's size. The effects of founders' personalities on the success of new ventures are, however, mainly unknown. Here, we show that founder personality traits are a significant feature of a firm's ultimate success. We draw upon detailed data about the success of a large-scale global sample of startups (n = 21,187). We find that the Big Five personality traits of startup founders across 30 dimensions significantly differ from that of the population at large. Key personality facets that distinguish successful entrepreneurs include a preference for variety, novelty and starting new things (openness to adventure), like being the centre of attention (lower levels of modesty) and being exuberant (higher activity levels). We do not find one 'Founder-type' personality; instead, six different personality types appear. Our results also demonstrate the benefits of larger, personality-diverse teams in startups, which show an increased likelihood of success. The findings emphasise the role of the diversity of personality types as a novel dimension of team diversity that influences performance and success.

Identifiants

pubmed: 37848462
doi: 10.1038/s41598-023-41980-y
pii: 10.1038/s41598-023-41980-y
pmc: PMC10582098
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17200

Informations de copyright

© 2023. Springer Nature Limited.

Références

Scand J Psychol. 2007 Dec;48(6):511-8
pubmed: 18028073
Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2215829120
pubmed: 37126710
PLoS One. 2013 Sep 25;8(9):e73791
pubmed: 24086296
Sci Rep. 2020 Jan 15;10(1):345
pubmed: 31941944
J Pers Soc Psychol. 2019 Sep;117(3):674-695
pubmed: 30113194
Science. 2015 Feb 6;347(6222):606-9
pubmed: 25657229
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26459-26464
pubmed: 31843929
Perspect Psychol Sci. 2007 Dec;2(4):313-45
pubmed: 26151971
J Pers Soc Psychol. 2001 Oct;81(4):670-83
pubmed: 11642353
Nat Commun. 2018 Dec 4;9(1):5163
pubmed: 30514841
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1036-40
pubmed: 25583507

Auteurs

Paul X McCarthy (PX)

The Data Science Institute, University of Technology Sydney, Sydney, NSW, Australia.
School of Computer Science and Engineering, UNSW Sydney, Sydney, NSW, Australia.

Xian Gong (X)

Faculty of Engineering and Information Technology, University of Technology Sydney, Sydney, Australia.

Fabian Braesemann (F)

Oxford Internet Institute, University of Oxford, Oxford, UK. fabian.braesemann@oii.ox.ac.uk.
DWG Datenwissenschaftliche Gesellschaft Berlin, Berlin, Germany. fabian.braesemann@oii.ox.ac.uk.

Fabian Stephany (F)

Oxford Internet Institute, University of Oxford, Oxford, UK.
DWG Datenwissenschaftliche Gesellschaft Berlin, Berlin, Germany.

Marian-Andrei Rizoiu (MA)

Faculty of Engineering and Information Technology, University of Technology Sydney, Sydney, Australia.

Margaret L Kern (ML)

Melbourne Graduate School of Education, The University of Melbourne, Parkville, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH